# reload+after+2024-01-23 20:43:33.528913
address1§630 5th Avenue
address2§20th Floor
city§New York
state§NY
zip§10111
country§United States
phone§844 689 3939
website§https://www.anavex.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
fullTimeEmployees§40
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Christopher U. Missling M.B.A., M.S., Ph.D.', 'age': 57, 'title': 'President, CEO, Secretary & Director', 'yearBorn': 1966, 'fiscalYear': 2023, 'totalPay': 828253, 'exercisedValue': 3203340, 'unexercisedValue': 15456209}, {'maxAge': 1, 'name': 'Ms. Sandra  Boenisch CPA, CGA', 'age': 42, 'title': 'Principal Financial Officer & Treasurer', 'yearBorn': 1981, 'fiscalYear': 2023, 'totalPay': 194358, 'exercisedValue': 0, 'unexercisedValue': 764381}, {'maxAge': 1, 'name': 'Mr. Stephan  Toutain M.B.A., M.S.', 'age': 57, 'title': 'Senior VP of Operations & COO', 'yearBorn': 1966, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Walter E. Kaufmann M.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Clint  Tomlinson', 'title': 'VP of Corporate', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Adebayo  Laniyonu Ph.D.', 'title': 'Senior Vice President of Nonclinical Development', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Edward R Hammond M.D., M.P.H., Ph.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Kun  Jin Ph.D.', 'title': 'Head of Biostatistics', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David  Goldberger R.Ph.', 'title': 'Senior Vice President of Regulatory Affairs', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§3
compensationRisk§8
shareHolderRightsRisk§1
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.686
currency§USD
dateShortInterest§1702598400
forwardEps§-0.31
exchange§NMS
quoteType§EQUITY
shortName§Anavex Life Sciences Corp.
longName§Anavex Life Sciences Corp.
firstTradeDateEpochUtc§1154525400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§a192134c-09ce-387b-bb62-3b271f6333ed
gmtOffSetMilliseconds§-18000000
targetHighPrice§40.0
targetLowPrice§25.0
targetMeanPrice§34.67
targetMedianPrice§39.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§12.265
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
